Krystal Biotech (KRYS) Expected to Announce Earnings on Monday

Krystal Biotech (NASDAQ:KRYS) is expected to be posting its quarterly earnings results before the market opens on Monday, February 24th. Analysts expect Krystal Biotech to post earnings of $1.29 per share and revenue of $91.35 million for the quarter. Individual that are interested in registering for the company’s earnings conference call can do so using this link.

Krystal Biotech Price Performance

KRYS stock opened at $153.24 on Monday. The firm’s fifty day simple moving average is $158.61 and its 200-day simple moving average is $175.74. The company has a market capitalization of $4.41 billion, a P/E ratio of 86.58 and a beta of 0.84. Krystal Biotech has a 12 month low of $107.50 and a 12 month high of $219.34.

Analyst Upgrades and Downgrades

A number of analysts recently issued reports on KRYS shares. Citigroup increased their price target on shares of Krystal Biotech from $204.00 to $206.00 and gave the stock a “neutral” rating in a report on Tuesday, November 5th. Chardan Capital reissued a “buy” rating and set a $212.00 price target on shares of Krystal Biotech in a report on Wednesday, December 18th. Finally, HC Wainwright reissued a “buy” rating and set a $221.00 price target on shares of Krystal Biotech in a report on Wednesday, December 18th. One equities research analyst has rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, Krystal Biotech currently has an average rating of “Buy” and a consensus target price of $206.67.

Insiders Place Their Bets

In other Krystal Biotech news, insider Suma Krishnan sold 25,000 shares of the company’s stock in a transaction on Friday, December 13th. The shares were sold at an average price of $164.78, for a total transaction of $4,119,500.00. Following the completion of the transaction, the insider now directly owns 1,475,882 shares in the company, valued at approximately $243,195,835.96. This represents a 1.67 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. 14.10% of the stock is currently owned by company insiders.

About Krystal Biotech

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).